## Weiguang Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7424547/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Disulfiram-mediated inhibition of NF-?B activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. International Journal of Cancer, 2003, 104, 504-511.	2.3	206
2	A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget, 2013, 4, 502-530.	0.8	152
3	Disulfiram/copper complex inhibiting NFκB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Letters, 2010, 290, 104-113.	3.2	112
4	Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2014, 5, 7471-7485.	0.8	103
5	Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2. Cell Death and Disease, 2017, 8, e2797-e2797.	2.7	103
6	Mechanistic and Predictive Profiling of 5-Fluorouracil Resistance in Human Cancer Cells. Cancer Research, 2004, 64, 8167-8176.	0.4	102
7	Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition. Journal of Translational Medicine, 2014, 12, 163.	1.8	81
8	Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 641-657.	1.7	68
9	The cytotoxic mechanisms of disulfiram and copper(ii) in cancer cells. Toxicology Research, 2015, 4, 1439-1442.	0.9	66
10	Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents. Frontiers in Molecular Biosciences, 2021, 8, 741316.	1.6	59
11	Development of Injectable PEGylated Liposome Encapsulating Disulfiram for Colorectal Cancer Treatment. Pharmaceutics, 2019, 11, 610.	2.0	53
12	Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 112, 224-233.	2.0	50
13	Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Letters, 2002, 531, 415-420.	1.3	46
14	Endothelial nitric oxide synthase activity is inhibited by the plasma membrane calcium ATPase in human endothelial cells. Cardiovascular Research, 2010, 87, 440-448.	1.8	46
15	Triptolide simultaneously induces reactive oxygen species, inhibits NF-κB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. Cancer Letters, 2010, 291, 200-208.	3.2	44
16	Disulfiram/copper complex activated JNK/c-jun pathway and sensitized cytotoxicity of doxorubicin in doxorubicin resistant leukemia HL60 cells. Blood Cells, Molecules, and Diseases, 2011, 47, 264-269.	0.6	42
17	Plasma Membrane Calcium ATPase Isoform 4 Inhibits Vascular Endothelial Growth Factor–Mediated Angiogenesis Through Interaction With Calcineurin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2310-2320.	1.1	41
18	Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemotherapy and Pharmacology, 2007, 59, 839-845.	1.1	39

WEIGUANG WANG

#	Article	IF	CITATIONS
19	Disruption of the interaction between PMCA2 and calcineurin triggers apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer cells. Carcinogenesis, 2012, 33, 2362-2368.	1.3	39
20	Triptolide, a Chinese herbal extract, enhances drug sensitivity of resistant myeloid leukemia cell lines through downregulation of HIF-11± and Nrf2. Pharmacogenomics, 2013, 14, 1305-1317.	0.6	35
21	Plasma membrane calcium ATPase proteins as novel regulators of signal transduction pathways. World Journal of Biological Chemistry, 2010, 1, 201.	1.7	33
22	Development of disulfiram-loaded vaginal rings for the localised treatment of cervical cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 945-953.	2.0	32
23	The interaction between endogenous calcineurin and the plasma membrane calciumâ€dependent ATPase is isoform specific in breast cancer cells. FEBS Letters, 2007, 581, 4115-4119.	1.3	31
24	Investigation of the key chemical structures involved in the anticancer activity of disulfiram in A549 non-small cell lung cancer cell line. BMC Cancer, 2018, 18, 753.	1.1	31
25	APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC Cancer, 2009, 9, 434.	1.1	27
26	Hot melt extruded and injection moulded disulfiram-loaded PLGA millirods for the treatment of glioblastoma multiforme via stereotactic injection. International Journal of Pharmaceutics, 2015, 494, 73-82.	2.6	23
27	Disulfiram-loaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer. Journal of Pharmacy and Pharmacology, 2015, 67, 189-198.	1.2	21
28	Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption. Oncotarget, 2016, 7, 85515-85528.	0.8	21
29	Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram/copper complex <i>in vitro</i> and <i>in vivo</i> in patient-derived xenograft models. Oncotarget, 2016, 7, 82200-82212.	0.8	17
30	Cyclodextrin Diethyldithiocarbamate Copper II Inclusion Complexes: A Promising Chemotherapeutic Delivery System against Chemoresistant Triple Negative Breast Cancer Cell Lines. Pharmaceutics, 2021, 13, 84.	2.0	15
31	How could a drug used to treat alcoholism also be effective against glioblastoma?. Expert Review of Anticancer Therapy, 2013, 13, 239-241.	1.1	14
32	Development of Disulfiram-Loaded Poly(Lactic-co-Glycolic Acid) Wafers for the Localised Treatment of Glioblastoma Multiforme: A Comparison of Manufacturing Techniques. Journal of Pharmaceutical Sciences, 2015, 104, 1076-1086.	1.6	10
33	Selective inhibition of plasma membrane calcium ATPase 4 improves angiogenesis and vascular reperfusion. Journal of Molecular and Cellular Cardiology, 2017, 109, 38-47.	0.9	10
34	218â€A Novel Role for the PMCA4-specific Inhibitor Aurintricarboxylic Acid as an Enhancer of VECF-Induced Angiogenesis. Heart, 2015, 101, A119.1-A119.	1.2	0
35	144â€Selective inhibition of plasma membrane calcium atpase 4 improves vegf-mediated angiogenesis. Heart, 2017, 103, A107.2-A107.	1.2	0